Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin dosing and review interval comparison in wet age-related macular degeneration
ISRCTN95654194Phase 4Completed
- Sponsor
- Nottingham University Hospitals
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of bevacizumab in exudative macular degeneration (4 arms), sponsored by Nottingham University Hospitals. Primary endpoint: Time to vision deterioration event. Started Jan 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ISRCTN95654194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95654194.